Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

1. Remon, J.
2. Besse, B.
3. Aix, S.P.
4. Callejo, A.
5. Al-Rabi, K.
6. Bernabe, R.
7. Greillier, L.
8. Majem, M.
9. Reguart, N.
10. Monnet, I.
11. Cousin, S.
12. Garrido, P.
13. Robinet, G.
14. Garcia Campelo, R.
15. Madroszyk, A.
16. Mazières, J.
17. Curcio, H.
18. Wasąg, B.
19. Pretzenbacher, Y.
20. Fournier, B.
21. Dingemans, A.-M.C.
22. Dziadziuszko, R.